We have recently begun acquiring a new position in Novo Nordisk. Click here for our investment thesis on NVO stock.

Novo Nordisk has rebounded strongly in 2025, backed by solid financials despite earlier setbacks and competitive risks. See ...

The major averages posted modest gains on Thursday, catching a tailwind from a cooler-than-anticipated inflation report.